Workflow
Phibro(PAHC)
icon
Search documents
Phibro(PAHC) - 2024 Q3 - Earnings Call Presentation
2024-05-09 19:52
Financial Performance - Q3 FY24 (Consolidated) - Total consolidated net sales increased by 7% year-over-year, from $245.7 million to $263.2 million[24] - Adjusted EBITDA increased by 9% year-over-year, from $27.4 million to $29.7 million[24] - Net income decreased by 16% year-over-year, from $10.0 million to $8.4 million[24] - Adjusted net income increased by 9% year-over-year, from $11.6 million to $12.7 million[24] Financial Performance - Q3 FY24 (Animal Health) - Animal Health net sales increased by 10% year-over-year, from $164.4 million to $181.3 million[27] - Vaccines sales increased by 26% year-over-year[7, 27] - MFAs (Medicated Feed Additives) and other sales increased by 16% year-over-year[7, 27] - Nutritional specialties sales decreased by 11% year-over-year[7, 27] - Animal Health adjusted EBITDA increased by 7% year-over-year, from $34.2 million to $36.5 million[27] Acquisition and Guidance - The company is set to acquire Zoetis' MFA and certain water-soluble products business for $350 million, subject to adjustments[7] - The company affirms fiscal year 2024 guidance with net sales of $980 million to $1.020 billion and adjusted EBITDA of $106 million to $112 million[7]
Phibro(PAHC) - 2024 Q3 - Quarterly Results
2024-05-08 20:41
Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance TEANECK, N.J., May 8, 2024 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its third quarter ended March 31, 2024 and its updated financial guidance for the year ending June 30, 2024. We affirm our ...
Phibro(PAHC) - 2024 Q3 - Quarterly Report
2024-05-08 20:10
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-184 ...
Phibro(PAHC) - 2024 Q2 - Earnings Call Transcript
2024-02-08 20:55
Phibro Animal Health Corporation (NASDAQ:PAHC) Q2 2024 Earnings Conference Call February 8, 2024 9:00 AM ET Company Participants Richard Johnson - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Daniel Bendheim - Executive Vice President, Corporate Strategy Glenn David - Incoming Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Mikaela Franceschina - Barclays Brian Wright - Roth MKM Operator Hello and thank you for standing by. My name ...
Phibro(PAHC) - 2024 Q2 - Quarterly Report
2024-02-07 21:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13- ...
Phibro(PAHC) - 2024 Q1 - Earnings Call Transcript
2023-11-10 16:35
Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2024 Earnings Conference Call November 9, 2023 9:00 AM ET Company Participants Daniel M. Bendheim - EVP, Corporate Strategy Jack C. Bendheim - Chairman, President & CEO Richard G. Johnson - Interim CFO Conference Call Participants Unidentified Analyst - Barclays Michael Ryskin - Bank of America Securities Brian Wright - ROTH MKM Partners Linda Bolduc - Morgan Stanley Operator Hello, and thank you for standing by. My name is Regina, and I will be your confere ...
Phibro(PAHC) - 2024 Q1 - Earnings Call Presentation
2023-11-09 18:07
Phibro Animal Health Corporation Webcast and Conference Call November 9, 2023 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: [3927884] November 9, 2023 Webcast & Conference Call Cautionary Statement Regarding Forward-Looking Statements Non-GAAP Financial Measures Internet Posting of Information This presentation is a supplement to, and should be read in conjunction with, Phibro Animal Health Corporation's earnings release for the quarter ended September 30, 2023. Key Themes ...
Phibro(PAHC) - 2024 Q1 - Quarterly Report
2023-11-08 21:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13 ...
Phibro(PAHC) - 2023 Q4 - Earnings Call Transcript
2023-08-31 17:27
Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2023 Results Conference Call August 31, 2023 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Donny Bendheim - Director and Executive Vice President, Corporate Strategy Conference Call Participants Brian Wright - ROTH MKM Michael Ryskin - Bank of America Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your operator today. At this ti ...
Phibro(PAHC) - 2023 Q4 - Annual Report
2023-08-30 20:22
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-1840497 (Sta ...